Vimarsana
Biggest News Aggregation in the World

Page 4 - Advanced Prostate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced Prostate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Prostate Today - Breaking & Trending Today

Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer - Vimarsana News

Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer

FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2...

Novartis PluvictoTM approved by FDA as first targeted - Vimarsana News

Novartis PluvictoTM approved by FDA as first targeted

Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68...

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer - Vimarsana News

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer

Novartis Pharma AG: Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer - Vimarsana News

Novartis Pharma AG: Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2 Metastatic

THE PROSTATE CANCER FOUNDATION ANNOUNCES 2021 CHALLENGE AWARDS TOTALING MORE THAN $9 MILLION FOR PROSTATE CANCER RESEARCH - Vimarsana News

THE PROSTATE CANCER FOUNDATION ANNOUNCES 2021 CHALLENGE AWARDS TOTALING MORE THAN $9 MILLION FOR PROSTATE CANCER RESEARCH

/PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2021 Class of PCF Team Challenge Award recipients and a total of more than $9 million...